D
David Chadwick
Researcher at James Cook University Hospital
Publications - 82
Citations - 3242
David Chadwick is an academic researcher from James Cook University Hospital. The author has contributed to research in topics: Population & Viral load. The author has an hindex of 22, co-authored 77 publications receiving 2582 citations. Previous affiliations of David Chadwick include South Tees Hospitals NHS Trust.
Papers
More filters
Posted ContentDOI
Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
Peter Horby,Wei Shen Lim,Jonathan Emberson,Marion Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,Christopher Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J Kenneth Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.
Journal Article
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Peter Horby,Wei Shen Lim,Jonathan Emberson,Marion Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,Christopher Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J Kenneth Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In this paper, the authors reported the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone, and the primary outcome was 28-day mortality.
Journal ArticleDOI
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
Robert C. Read,David Baxter,David Chadwick,Saul N. Faust,Saul N. Faust,Adam Finn,Stephen B. Gordon,Paul T. Heath,David J. M. Lewis,Andrew J. Pollard,David P. J. Turner,Rohit Bazaz,Amitava Ganguli,Tom Havelock,Tom Havelock,Keith R. Neal,Ifeanyichukwu O Okike,Begonia Morales-Aza,Kamlesh Patel,Matthew D. Snape,John Williams,Stefanie Gilchrist,Steve J. Gray,Martin C. J. Maiden,Daniela Toneatto,Huajun Wang,Maggie McCarthy,Peter M. Dull,Ray Borrow,Ray Borrow +29 more
TL;DR: Although there was no significant difference between groups at 1 month after vaccine course, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vaccination and therefore might affect transmission when widely implemented.
Posted ContentDOI
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby,Guilherme Pessoa-Amorim,Leon Peto,Christopher E. Brightling,Rahuldeb Sarkar,Karen Thomas,V Jeebun,Abdul Ashish,R Tully,David Chadwick,M Sharafat,Richard B. Stewart,B Rudran,Kenneth Baillie,Maya H Buch,Lucy C Chappell,Jeremy N. Day,S Furst,Thomas Jaki,Katie Jeffery,Edmund Juszczak,Wei Shen Lim,Alan A Montgomery,Andrew D Mumford,Kathy Rowan,G Thwaites,M Mafham,Richard Haynes,Martin J Landray +28 more
TL;DR: In this article, the authors evaluated the safety and efficacy of tocilizumab in adult patients admitted to hospital with COVID-19 with evidence of both hypoxia and systemic inflammation.
Journal ArticleDOI
British HIV Association guidelines for immunization of HIV-infected adults 2008.
Anna Maria Geretti,Gary Brook,Claire Cameron,David Chadwick,Robert S. Heyderman,Eithne MacMahon,Anton Pozniak,Mary Ramsay,M Schuhwerk +8 more
TL;DR: Geretti et al. as discussed by the authors proposed a general principles of immunization in HIV-infected adults, including the following: 1.1 Vaccine efficacy 2.2 Vaccine safety 2.3 Contraindications 3.2 Epidemiology and risk groups 3.3 Anthrax vaccine 2.4 Recommendations for anthrax pre-exposure prophylaxis 3.0 Cholera vaccine 4.3.